Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine

Date: March 9, 2020 Issue #: 1593Summary: Lasmiditan (Reyvow– Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy– Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.

http://secure.medicalletter.org/TML-article-1593b

Source: The Medical Letter - February 4, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Aimovig Ajovy Almotriptan Amerge Cafergot Cambia D.H.E. 45 Diclofenac Dihydroergotamine Eletriptan Emgality erenumab fremanezumab Frova Frovatriptan galcanezumab Imitrex lasmiditan Maxalt Migergot Migraine Migrana Source Type: research